Jun 5, 2026 05:04PM
May 26, 2026 08:01AM
Apr 30, 2026 08:03AM
Apr 22, 2026 07:01AM
Feb 23, 2026 08:02AM
Feb 10, 2026 08:00AM
Jan 6, 2026 07:01AM Genprex reports preclinical data for diabetes gene therapy GPX-002
Nov 21, 2025 04:59PM
Nov 18, 2025 07:00AM
Nov 4, 2025 07:02AM
Oct 28, 2025 07:00AM
Oct 23, 2025 07:02AM
Sep 12, 2025 04:48PM
Aug 4, 2025 08:31AM Genprex issues stockholder letter with 2025 corporate update
Jun 24, 2025 09:25AM
Apr 28, 2025 07:30AM
Apr 22, 2025 08:15AM
Mar 26, 2025 08:16AM
Feb 19, 2025 08:16AM
Feb 18, 2025 08:16AM
Dec 16, 2024 09:15AM Genprex (GNPX) Receives Safety Review Committee Approval to Advance to Phase 2 Portion of Acclaim-3 Clinical Trial of Reqorsa® Gene Therapy in Combination with Tecentriq in Extensive Stage Small Cel
Nov 20, 2024 09:29AM
Nov 5, 2024 09:30AM
Oct 28, 2024 09:30AM
Oct 24, 2024 09:30AM
Oct 15, 2024 09:29AM
Sep 19, 2024 09:29AM
Sep 4, 2024 09:29AM Genprex (GNPX) to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes
Aug 14, 2024 09:25AM
Aug 13, 2024 08:31AM

416,796 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All